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Abstract
Background: The failure of specific types of human papillomaviruses (HPV) to raise effective immune responses
may be important in the pathogenesis of cervical cancer, the second most common cancer in South African
women. Polymorphisms of a number of cytokine genes have been implicated in inducing susceptibility or
resistance to cancers caused by infectious agents owing to their role in determining host immune response.
Polymorphisms of IL-10 and IFN-γ genes are believed to influence the expression and/or secretion levels of their
respective cytokines.
Methods and Results: In this study, women with histologically proven cancer of the cervix (n = 458) and
hospital-based controls (n = 587) were investigated for bi-allelic -1082 (A/G) polymorphisms of IL-10 and the bi-
allelic +874(A/T) polymorphisms of IFN-γ. In addition, the distributions of the allelic frequencies were stratified
in both the African and mixed race population groups of South Africa. We found striking differences in the allele
distribution of IFN-γ (X2 = 0.02) among the two ethnic groups. A significant increase in the allele distribution of
the IFN-γ AA genotype was found in the African group compared to the mixed population group (OR, 0.5; 95%
CI, 0.2–1.0). For IL-10 there were no significant allelic differences between the two South African ethnic groups.
Furthermore, when the ethnic groups were combined the IL-10 allelic frequencies in the combined South African
data were similar to those observed in an Oriental population from Southern China and in an Italian population.
However, the allele frequencies of the IFN-γ genotype among the two South African ethnic groups were different
when compared to an Italian Caucasoid group. While crude analysis of these data showed both statistically
significantly increased and diminished risks of cervical cancer among high producers of INF-γ and low producers
of IL-10 respectively, these associations were no longer significant when the data were adjusted for confounding
factors.
Conclusion: These findings demonstrate a clear correlation between ethnicity and IFN-γ polymorphism across
different population groups. However, these differences in ethnicity and gene polymorphisms in the
aforementioned cytokines are suggested not to influence the development of invasive cervical cancer but may
represent an important susceptibility biomarker for other diseases and should be explored further.
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Background
The major cause of cervical cancer is due to infection with
specific high-risk types of HPV. [1–3] In South Africa inva-
sive cancer of the cervix is the second most common can-
cer among women, with an age-standardized incidence
rate of 15 for Asians, 26.5 for Africans, 17.7 for mixed race
and 10.8 for Caucasians.[4] Although the incidence of
genital HPV infection in various population groups is
high most of these regress without intervention.[5] Inves-
tigating genetic host factors and immune responses could
help to understand the association between genital HPV
infection and carcinogenesis. In particular, cell-mediated
immunity (CMI) is important in controlling both HPV
infections and HPV-associated neoplasms. [6] CMI is reg-
ulated by cytokines that are secreted primarily by T helper
(Th) cells and macrophages; Th cells are classified into
two distinct subsets of cells according to their cytokine
pattern. Th1 modulates cellular (type 1) and Th2 humoral
(type 2) immune responses.[7] Th1 cells produce inter-
feron-gamma (IFN-γ) and interleukin 2 (IL-2), which are
immuno-stimulatory and are associated with the clear-
ance of HPV infection and regression of cervical intraepi-
thelial neoplasia.[8] Th2 cells produce IL-4 and IL-10,
which are immuno-inhibitory and are capable of stimu-
lating tumor growth.[9] Several studies have identified
polymorphisms in cytokine gene regulatory regions that
correlated to intra-individual variations in cytokine pro-
duction. [10–12] In addition, cytokine gene polymor-
phisms have been implicated in various neoplastic and
non-neoplastic human pathologies[13] and in a number
of diseases including Epstein-Barr virus associated gastric
carcinoma,[14] Alzheimer's,[15] rheumatoid arthritis[16]
and in patients presenting with severe sepsis after
trauma.[17] Others have documented the relationship of
an increased type 2 and decreased type 1 cytokine profile
to a range of tumours[9,18–20] and demonstrated the
association of cytokine polymorphism with the risk and
prognosis of cervical cancer. [21–23] Such efforts have
generated many candidates and have shown that a
decreased IFN-γ transcription and increased IL-10 tran-
scription in the sub-epithelial tissues in patients with
HPV-16 positive cervical intraepithelial neoplasia (CIN) is
reported to play a role in the development and progres-
sion of HPV-16 associated cervical precancer.[24] Conse-
quently the potential importance of type 1 and type 2
polymorphism of cytokines such IL-10 and IFN-γ in cervi-
cal cancer are of great interest.
IFN-γ plays a pivotal role in defense against viruses and
intracellular pathogens and in the induction of immune-
mediated inflammatory responses.[25] Pravica et al., 2000
noted a novel single nucleotide polymorphism (SNP), T
to A, located at the +874 position from translation start
site in the first intron of IFN-γ gene, which coincides with
a putative NF-κB binding site that could play a fundamen-
tal role in the induction of constitutively high IFN-γ pro-
duction. The association of +874 alleles T to A with a low
(AA), medium (AT) and high (TT) cytokine production
was shown in vitro.[26] The same group reported a
number of polymorphisms in the IL-10 gene of which the
SNP situated at the -1082 position of the promoter region
of the IL-10 gene plays an important role in determining
high, medium and low production of IL-10.[27] The asso-
ciation of G/A SNP at position -1082 has been associated
with low (AA), medium (AG) and high (GG) cytokine
production were shown in vitro.[27]
Several studies have demonstrated that ethnicity and
cytokine polymorphism plays a significant role in the sus-
ceptibility to a wide range of diseases [28–30] including
cervical cancer [21,22]. We thus determined the allelic
and genotype frequencies of +874 IFN-γ and -1082 IL-10
genes using the ARMS-PCR methodology among two
South African ethnic groups and investigated their rela-
tionship to the development of cervical cancer. Using pre-
viously collected data on known and suspected risk factors
to adjust for confounding,[31] we found a significant dif-
ference in the distribution of the bi-alleleic +874 IFN-γ
gene among the black and mixed population groups in
South Africa. Similarly, we found a pronounced difference
in the frequency of IFN-γ when compared to published
data from three other groups of different ethnic origin.
Interestingly, we did not observe a significant association
between cytokine polymorphisms and susceptibility or
resistance to developing cervical cancer. We postulate that
the non-association between cervical cancer and the afore-
mentioned cytokine gene polymorphisms is multi-facto-
rial and may be a consequence of biologic factors,
ethnicity, socioeconomic risk factors and life style. In
addition, we reasoned that while others have generated
strong correlation between cytokine polymorphism and
the development of cervical cancer,[32,33] these studies
might have been designed to have insufficient statistical
power to examine these relationships adequately. These
results also suggest that the disparity observed in the
ethnic groups in South Africa may influence immune
responses in other diseases as reported in several South
African studies. [34,28]
Methods
Patients and Control populations
Individuals were selected from a cancer case-control study
conducted in the Western Cape Province of South Africa,
from January 1998 to December 2001.[31] Data on
known risk factors and potential confounders was col-
lected using a detailed questionnaire administered by
trained nurse interviewers. Blood samples from 458
patients with cervical cancer and 587 hospital-based con-
trols were analysed for IL-10 and IFN-γ gene polymor-
phisms. All of the patients and hospital based controlsJournal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/3
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with conditions unrelated to the use of hormonal contra-
ception and no history and evidence of cervical disease
were from the mixed race and African population groups
residing in the Western Cape Province of South Africa.
DNA extraction
Genomic DNA was extracted from whole blood using the
QiAamp Spin Blood Kit (QIAGEN, Valencia, CA) in
accordance with manufacturer's instructions.
Cytokine genotyping
The A and T alleles at position +874 in the first intron of
the IFN-γ gene and the A and G alleles at position -1082
in the promoter region of the IL-10 gene were identified
using the amplification refractory mutation system
polymerase chain reaction (ARMS-PCR) methodology as
previously described.[35] The amplified ARMS-PCR prod-
ucts were then visualized by electrophoresis in 2 % agar-
ose gel stained with ethidium bromide.
Statistical analysis
All statistical analyses were performed using PC SAS ver-
sion 6.12 (SAS Institute Inc., Cary NC). Allelic frequencies
between patients and control groups and ethnic popula-
tions were compared using the X2 test. Unconditional
logistic regression was used to estimate odds ratios (OR's)
for developing cancer of the cervix in relation to the
cytokine polymorphisms. These OR's were adjusted for
the following confounding factors; ethnic group, 5 year
age group, years of education, age at first sexual inter-
course, number of sexual partners, urban/rural living,
number of Pap smears, injectable/oral contraceptive use,
smoking, and parity, IL-10 and IFN-γ.
Results
To investigate the reproducibility of the assigned geno-
types thirty samples were randomly chosen and their gen-
otypes confirmed by repeating the ARMS-PCR.
Allelic frequencies were compared using the X2 test and
confirmed for their fit to the Hardy-Weinberg equilibrium
test. The allele frequencies for IFN-γ +874 in the cases and
controls among the two ethnic groups are reported in
Table 1. The allelic distribution for IFN-γ was significantly
different (X2 = 0.02) between the two ethnic groups. Spe-
cifically, the frequency of the IFN-γ AA genotype was sig-
nificantly higher among the African population and was
associated with a decreased risk of cervical cancer and this
association was of borderline significance when the data
was adjusted for IL-10 (OR, 0.5; 95% CI, 0.2–1.0). More-
over, in the combined South African data the distribution
of the IFN-γ AA genotype was significantly different when
adjusted for ethnicity and IL-10 however this difference
was longer significant when the data was adjusted for
known risk factors and confounding factors. There were
no significant differences in the distribution of IFN-γ
allelic polymorphism in the controls and cases with cervi-
cal cancer.
The allelic frequencies for the polymorphism at position -
1082 of the IL-10 promoter gene in the cases with cervical
cancer and controls are shown in Table 2. Borderline sig-
nificance in the association between the distribution of -
1082 IL-10 alleles and susceptibility or resistance to cervi-
cal cancer was noted in the crude data (OR, 0.6; 95% CI,
0.3–1.0) and when it was adjusted for IFN-γ (OR, 0.6;
95% CI, 0.3–1.0). However, when the data was adjusted
for potential confounding factors, no significant associa-
tion was observed (OR, 0.6; 95% CI, 0.3–1.2). Similar
results were obtained when the cases and controls were
stratified into the two ethnic population groups (data not
shown).
Logistic regression estimates for developing cancer of the
cervix in relation to gene polymorphisms of -1082 IL-10
and +874 IFN-γ are shown in Table 3. Since associations
of borderine significance were observed in the risk for
developing cervical cancer in the high and low producing
alleles for INF-α (Table 1) and IL-10 (Table 2) when com-
pared to the medium producing alleles, we aimed at fur-
ther investigating the risk associated for the respective
high and low producing alleles for the aforementioned
cytokines. These estimates are shown in Table 3. There
was a significant difference in the allelic distribution of
IFN-γ T allele in the combined data which leads to an
increased risk of cervical cancer but only when adjusted
for the IL-10 data (OR, 3.7; 95% CI, 1.2–11.0). Similarly,
for IL-10 borderline significance was observed in the dis-
tribution of the IL-10G allele in the combined data while
adjusting for the IFN-γ data (OR, 0.5; 95% CI, 0.2–1.0).
There were no significant associations between these
cytokine polymorphisms and susceptibility or resistance
to cervical cancer when the risk estimates were adjusted
for known risk factors and possible confounding factors.
Table 4 shows the allele frequencies of IL-10 and INF-γ in
our two control ethnic groups and compares them to
other population studies. Allele frequencies for the com-
bined South African data for IL-10 were similar to those
reported in an Italian[36] and not significantly different
from two British Caucasoid groups.[37,38] There was an
increased frequency of the IL-10 A allele and decrease in
the G allele in the Chinese population[39] when com-
pared to the South African data and other population
groups. There was an increased frequency of the IFN-γ A
allele in the African and mixed race groups, compared
with that found in an Italian Caucasian population. It is
difficult to compare our data to the Italian Caucasoid data
since we do not have the raw data from their study, but it
is clear that 61% and 77% are significantly greater propor-Journal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/3
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tions than 32%. There was a significant difference in the
distribution of the INF-γ A allele when the mixed race
group and African groups were compared (p < 0.007) and
no significance in the distribution for the TT (p < 0.06)
and TA (0.07) genotypes.
Discussion
Several studies have investigated the possible role of
cytokine gene polymorphisms and the prevalence of HPV-
induced cervical cancer.[32,40] This impairment of host
factors might result in susceptibility or resistance to tumor
progression. Other studies have included ethnicity as a
factor in identifying impairments where the distribution
of alleles across populations may influence the outcome
of disease.[21,33,41,42] In this study we noted significant
differences in the distribution of +874 IFN-γ alleles com-
pared to the distribution for -1082 IL-10 alleles among the
African and mixed race groups in South Africa.
Although our study did not find a correlation between
IFN-γ and IL-10 gene polymorphisms and the risk for
developing cancer of the uterine cervix, it is powered by
strong statistical analysis. We adjusted for all known risk
factors and possible confounding factors for the develop-
ment of cervical cancer including IL-10 and IFN-γ. As the
aforementioned cytokines are important immuno-modu-
lators and contribute to the development and progression
of cervical cancer, [9,24] it was important to adjust each
one against the other as a potential confounder. In addi-
tion, IL-10 has anti-inflammatory capabilities that can
down-regulate the production of IFN-γ, [28] thus poly-
morphisms of these cytokines may interact with each
other and influence disease progression.
To the best of our knowledge this is the first study investi-
gating the genetic association of polymorphisms in the
+874 IFN-γ gene with cervical cancer among two racially
Table 1: Odds Ratios and 95% confidence intervals for the development of cervical cancer in relation to INF-γ +874 alleles among the 
cervical cancer cases and controls in two South African ethnic populations.
Race Genotype CaCx n (%) Controls* n (%) OR1 (95% CI) OR2 (95% CI) OR3 (95% CI)
1. All# (n = 261) (n= 405)
TT 19 (7) 33 (8) 0.7(0.4–1.3) 1.0(0.4–2.3) 0.8(0.3–2.1)
AA 146 (56) 260 (64) 0.6(0.5–0.9) 0.6(0.4–0.9) 0.7(0.4–1.1)
AT 96 (37) 112 (28) 1.0 1.0 1.0
2. Mixed race (n = 165) (n= 265)
TT 14 (8) 26 (10) 0.7(0.3–1.4) 1.2(0.4–3.2) 1.0(0.3–3.1)
AA 85 (52) 158 (59) 0.7(0.4–1.0) 0.7(0.4–1.2) 0.7(0.3–1.3)
AT 66 (40) 81 (31) 1.0 1.0 1.0
3. African (n = 96) (n = 140)
TT 5 (5) 7 (5) 0.7(0.2–2.6) 0.7(0.2–3.0) 0.4(0.2–2.3)
AA 61 (64) 102 (73) 0.6(0.3–1.1) 0.5(0.2–1.0) 0.6(0.3–1.4)
AT 30 (31) 31 (22) 1.0 1.0 1.0
#All (1) = Mixed race (2) and African (3) population groups combined OR1 = crude odds ratio adjusted for ethnic group in the combined ethnic 
group analysis OR2 = adjusted for IL-10 OR3 = adjusted for ethnic group (only in the analysis combining Mixed race and African groups), 5 year age 
group, education, age at first sex, number of sexual partners, urban/rural living, number of pap smears, injectable/oral contraceptive use, smoking, 
parity and IL-10
Table 2: Odds Ratios and 95% confidence intervals for cervical cancer in relation to -1082 IL-10 alleles in South African cervical cancer 
cases (CaCx) and controls.
Genotype CaCx* (n = 197) n (%) Controls* (n = 182) n 
(%)
OR1 (95% CI) OR2 (95% CI) OR3 (95% CI)
GG 29 (15) 41 (23) 0.6(0.3–1.0) 0.6(0.3–1.0) 0.6(0.3–1.2)
AA 88 (45) 76 (42) 0.9(0.6–1.5) 1.0(0.6–1.6) 1.0(0.6–1.6)
AG 80 (41) 65 (36) 1.0 1.0 1.0
*Data given as percentages (As there were no differences in the distribution of IL-10 alleles between the mixed race and African groups the data 
was combined) OR1 = crude odds ratio OR2 = crude OR adjusted for IFN-γ OR3 = adjusted for ethnic group, 5 year age group, years of education, 
age at first sexual intercourse, number of sexual partners, urban/rural living, number of Pap smears, injectable/oral contraceptive use, smoking, par-
ity, and IFN-γ.Journal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/3
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different ethnic groups within South Africa. We found a
significant difference in the distribution of the IFN-γ AA
genotype in the combined South African data when
adjusted for ethnicity and IL-10. However, when the data
was adjusted for known risk factors and potential con-
founders the association between IFN-γ gene polymor-
phism and the risk for developing cancer of the uterine
cervix was no longer significant. In addition, we observed
a pronounced increase in the distribution of IFN-γ A allele
among the African group compared to the mixed popula-
tion group, which correlated with a decreased risk of
developing cervical cancer when adjusted for IL-10. This
result is of interest as several studies have reported that the
IFN-γ A allele is associated with the development of dis-
ease. [43–45] Nevertheless, as this is the first IFN-γ gene
polymorphism association study there are no compara-
tive data with which to compare our results. We observed
no significant association between IFN-γ and IL-10 gene
polymorphisms and cancer of the uterine cervix when the
analyses included control for confounding factors.
Table 3: Odds Ratios and 95% confidence intervals CI for developing cancer of the cervix in relation to genotypes considered as high or 
low producers of 1. -1082 IL-10 and 2. +874 IFN-γ.
Cytokine Race *Genotype CaCx n (%) Controls n (%) OR1 (95% CI) OR2 (95% CI) OR3 (95% CI)
1. IL-10 All# n = 117 n = 117
GG 29 (25) 41 (35) 0.6(0.3–1.0) 0.5(0.2–1.0) 0.6(0.3–1.2)
AA 88 (75) 76 (64) 1.0 1.0 1.0
2. IFN-γ All# n = 165 n = 299
TT 19 (12) 33 (11) 1.2(0.6–2.2) 3.7(1.2–11.0) 1.1(0.5–2.7)
AA 146 (88) 266 (89) 1.0 1.0 1.0
Mixed n = 99 n = 184
TT 14 (14) 26 (14) 1.0(0.5–2.2) 3.7(0.9–15.6) 1.5 (0.4–4.8)
AA 85 (86) 158 (86) 1.0 1.0 1.0
African n = 66 n = 109
T T 5  ( 8 )7  ( 6 )1 . 6 3 . 2 ( 0 . 6–18.0) 0.8(0.2–4.2)
AA 61 (92) 102 (94) (0.4–6.3) 1.0 1.0 1.0
#All = Mixed race and African population groups (As there were no differences in the distribution of IL-10 alleles between the two South African 
ethnic populations, the data was combined) *Genotype = (TT and GG associated with high cytokine secretion and the AA associated with low 
cytokine secretion) OR1 =crude odds ratio (high secreting allele vs low secreting allele) OR2 = crude odds ratios, IFN-γ data adjusted for IL-10 and 
IL-10 data adjusted for IFN-γ OR3 = fully adjusted for ethnic group, 5 year age group, education, age at first sex, number of sexual partners, urban/
rural living, number of pap smears, injectable/oral contraceptive use, smoking, parity and IFN-γ data adjusted for IL-10 and IL-10 data adjusted for 
IFN-γ
Table 4: Frequencies (%) of 1. IFN-γ genotype and 2. IL-10 (estimated by the Hardy-Weinberg Equilibrium) alleles in African and mixed 
race ethnic control groups and other populations.
Allele South African #Italian Caucasians +South-east 
England
†Manchester, UK §China
African Mixed race
1. IFN-γ (n = 103) (n = 188) (n = 363)
+874T/T 4 10 21.2 - - -
+ 8 7 4 T / A 1 92 94 6 . 8 - - -
+ 8 7 4 A / A 7 76 13 2 . 0 - - -
2. IL-10 *(n = 182) (n = 726) (n = 152) (n = 660) (n = 166)
-1082A 60 63 47.4 51 94
-1082G 40 37 52.6 49 6.0
*Combined African and mixed race control groups in this study (As there were no differences in the distribution of IL-10 alleles between the two 
South African ethnic populations, the data was combined to compare allele frequencies to other populations). Data reported by #Poli et al. (2002); 
+Reynard et al. (2000); †Perrey et al. (1998); §Mok et al. (1998)Journal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/3
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Our findings are discordant with those reported by Stanc-
zuk et al., 2001, who also investigated the association of -
1082 IL-10 gene polymorphism with cervical cancer. They
demonstrated that women who were predisposed to pro-
ducing high or medium levels of IL-10 were more likely to
develop cervical cancer than subjects who were predis-
posed to producing low levels of IL-10.[32] However,
their study was based on a small sample size and no
adjustment for known risk factors for cervical cancer was
made. Previous studies on the level of IL-10 production
have also been conflicting.[27,46] It was found that the -
1082 G and A alleles were correlated with low (AA),
medium (AG) and high (GG) levels of IL-10 production
as measured in in vitro stimulated peripheral blood lym-
phocytes.[27] Similarly, in an association study of IL-10
haplotypes and juvenile rheumatoid arthritis individuals
that are homozygous for -1082A allele (ATA/ATA) pro-
duced less IL-10 than those without the ATA haplo-
type.[47] Nevertheless, the considered low producing
haplotype was not associated with disease. However,
other groups have reported that the -1082A allele was
associated with high IL-10 production.[46,48] Helminen
et al., 2001 investigated the association of IL-10 gene pol-
ymorphism and susceptibility to primary Eptein-Barr
virus (EBV) infections. They reported that the -1082A
allele was associated with a poorer clinical outcome[49]
and measured spontaneous plasma levels by enzyme
immunoassay. It was found that the ATA haplotype was
associated with both high levels of IL-10 production and
an increased risk for symptomatic disease.[49]
Recently, various groups raised the issue of whether the
risk of developing cervical cancer is influenced by the
hosts' cytokine profile. Ghaderi et al., 2000 reported that
the tumor necrosis factor (TNF) a-11 allele was more fre-
quent in HPV16-seropositive cervical intraepithelial neo-
plasia (CIN) patients and in HLA-DR15-DQ6 positive
patients among Swedish women with cervical cancer. It
was suggested that the combination of these three markers
may increase the risk for developing CIN. Additionally,
several reports have investigated the serum levels of
cytokines in women with cervical cancer. Increased levels
of IL-6 and IL-8 in cervicovaginal secretions,[50] elevated
serum levels of IL-8, IL-10, TNF-beta, TNF-alpha and GM-
CSF[51] and a reduced IFN-γ transcription in both epithe-
lial and sub-epithelial zones,[24] have been found in
patients with cervical cancer. Furthermore, several studies
have demonstrated the association of p53 with cancer of
the uterine cervix, however, the functional relevance of
this polymorphism is in contention. It was shown that the
proline/proline genotype at codon 72 of p53 represented
a significant risk factor for the development of cervical
cancer, [41,52] while others have reported that the
arginine/arginine genotype was associated with cervical
cancer. [53–55] This disparity was suggested to be a man-
ifestation of geographic or ethnic variation of the popula-
tion study [41,56]
Several studies in cervical cancer survival have suggested
that the higher mortality rates in black populations is
explained primarily by the more advanced clinical stage at
time of diagnosis.[57,58] Furthermore, this variation in
cervical cancer mortality according to ethnicity may be
attributed to the unavailability of screening services, less
aggressive treatment patterns, greater clinical severity of
disease and unfavorable socioeconomic status in black
women with cervical cancer.[57,59] Similarly, in South
Africa, cancer of the cervix is the most common cancer in
African women (31.2%) compared to white women
(2.7%) and the incidence rates are comparable to those
found in the rest of Africa and other countries.[4]
The high degree of ethnic disparity in susceptibility to can-
cer of the cervix has sparked interest in identifying a refer-
ence population for investigating the distribution of
cytokine allele frequencies in different normal population
groups. When our control study groups were compared to
those of other population groups (Table 4) the distribu-
tion of the allele frequencies for -1082 IL-10 were similar
to those observed in three European Caucasoid groups
but differed from that found in a Chinese population. For
IFN-γ, the allele frequencies among the African and mixed
population group were disparate when compared to an
Italian Caucasoid population. These data highlight the
possible variability of cytokine gene frequencies in differ-
ent population groups and may be of relevance in other
infectious diseases.
Conclusion
Polymorphisms within cytokine genes can serve as immu-
nologic markers for identifying individuals at risk for dis-
ease. However, caution should be taken when association
studies are considered as there are several potential con-
founding factors that may contribute to the progression of
disease and cytokine polymorphisms should not be
viewed in isolation. Nevertheless, in this study we con-
clude that the allele distribution of IFN-γ +874 gene poly-
morphism was significantly different among the South
African and other ethnic population groups and this dis-
parity might have a significant consequence in the clinical
outcome of other diseases and may account for variation
in host susceptibility. Although our study did not show an
association between IL-10 -1082 and IFN-γ +874 gene
polymorphisms and the risk of developing cervical cancer
on the available data we question whether any particular
cytokine can be responsible for the development of cancer
of the uterine cervix. These data highlight the need for fur-
ther studies to clarify the association of ethnic variation
and cytokine polymorphism and the need for carefulJournal of Carcinogenesis 2003, 2 http://www.Carcinogenesis.com/content/2/1/3
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study design and adequate sample sizes to ensure that
spurious associations are not reported.
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